Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 Pharmaceutical Investing
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity Biotech Investing
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results Pharmaceutical Investing
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Biotech Investing
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review Biotech Investing
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Biotech Investing
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B Biotech Investing
